The board of directors of Huakang Biomedical Holdings Company Limited announced that Dr. Yeung has resigned as an INED and ceased to act as a member of the audit committee, remuneration committee and nomination committee of the Company with effect from 16 December 2020, as he intended to devote more time to his other personal business and commitments. The Board is pleased to further announce that Dr. Chow has been appointed as an INED and as a member of the audit committee, remuneration committee and nomination committee of the Company with effect from 16 December 2020. Dr. Chow, aged 47, has more than 20 years of experiences in the fields of biomedical testing and molecular diagnostics technology. Prior to joining the Group, Dr. Chow has ample experience in commercializing technologies. His co-inventions on the detection for human papilloma virus (commonly known as HPV, being a group of virus, a number of which are capable of infecting the genital areas of humans and may cause cervical and genital cancers) and other more rapid biomedical testing methods have been applied and commercialized for uses in market. Dr. Chow graduated from the Monash University in October 1997 with a degree in the Bachelor of Science. He obtained a Master of Medical Sciences degree and a Doctor of Philosophy degree in November 2000 and November 2007 respectively in the University of Hong Kong. In August 2006, Dr. Chow joined Diagcor Bioscience Incorporation Limited ("Diagcor Bioscience") as a research and development manager to develop new commercial products. He was subsequently promoted in 2013 as Diagcor Bioscience's general manager to focus on developing business strategies and overseeing the business growth of Diagcor Bioscience.